| [1] |
Zhou Y, Zheng M, Gong YF, et al. Changing seroprevalence of schistosomiasis Japonica in China from 1982 to 2020: a systematic review and spatial analysis[J]. PLoS Negl Trop Dis, 2024, 18(9):e0012466.
doi: 10.1371/journal.pntd.0012466
URL
|
| [2] |
Wilson MS, Mentink-Kane MM, Pesce JT, et al. Immunopathology of schistosomiasis[J]. Immunol Cell Biol, 2007, 85(2):148-154.
doi: 10.1038/sj.icb.7100014
pmid: 17160074
|
| [3] |
de Menezes Neves PDM, Jorge LB, Cavalcante LB, et al. Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes[J]. Clin Nephrol, 2020, 93(5):251-261.
doi: 10.5414/CN110013
URL
|
| [4] |
Liao ZN, Tao LJ, Yin HL, et al. Schistosoma japonicum infection associated with membranous nephropathy: a case report[J]. BMC Infect Dis, 2022, 22(1):125.
doi: 10.1186/s12879-022-07092-0
|
| [5] |
Houba V. Experimental renal disease due to schistosomiasis[J]. Kidney Int, 1979, 16(1):30-43.
pmid: 119088
|
| [6] |
赵成思, 秦敏, 谭明娟,等. 吡喹酮对日本血吸虫急性感染小鼠肾脏功能损伤的影响[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2):200-209.
doi: 10.12140/j.issn.1000-7423.2021.02.013
|
| [7] |
Liu ZL, Zhang LC, Liang YM, et al. Pathology and molecular mechanisms of Schistosoma japonicum-associated liver fibrosis[J]. Front Cell Infect Microbiol, 2022, 12:1035765.
doi: 10.3389/fcimb.2022.1035765
URL
|
| [8] |
Hu HH, Chen DQ, Wang YN, et al. New insights into TGF-β/Smad signaling in tissue fibrosis[J]. Chem Biol Interact, 2018, 292:76-83.
doi: 10.1016/j.cbi.2018.07.008
URL
|
| [9] |
Lathan R. Exploring unconventional targets in myofibroblast transdifferentiation outside classical TGF-β signaling in renal fibrosis[J]. Front Physiol, 2024, 15:1296504.
doi: 10.3389/fphys.2024.1296504
URL
|
| [10] |
Feng LX, Chen C, Xiong X, et al. PS-MPs promotes the progression of inflammation and fibrosis in diabetic nephropathy through NLRP3/Caspase-1 and TGF-β1/Smad2/3 signaling pathways[J]. Ecotoxicol Environ Saf, 2024, 273:116102.
doi: 10.1016/j.ecoenv.2024.116102
URL
|
| [11] |
Schwalm S, Beyer S, Frey H, et al. Sphingosine kinase-2 deficiency ameliorates kidney fibrosis by up-regulating Smad7 in a mouse model of unilateral ureteral obstruction[J]. Am J Pathol, 2017, 187(11):2413-2429.
doi: S0002-9440(17)30317-6
pmid: 28807595
|
| [12] |
Hong Q, Kim H, Cai GY, et al. Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy[J]. Int J Biol Sci, 2025, 21(4):1649-1665.
doi: 10.7150/ijbs.101548
pmid: 39990662
|
| [13] |
de Freitas Galvão RL, Meneses GC, Pinheiro MCC, et al. Kidney injury biomarkers and parasitic loads of Schistosoma mansoni in a highly endemic area in northeastern Brazil[J]. Acta Trop, 2022, 228:106311.
doi: 10.1016/j.actatropica.2022.106311
URL
|
| [14] |
van Velthuysen ML, Florquin S. Glomerulopathy associated with parasitic infections[J]. Clin Microbiol Rev, 2000, 13(1):55-66.
doi: 10.1128/CMR.13.1.55
pmid: 10627491
|
| [15] |
Zhang WJ, Chen SJ, Zhou SC, et al. Inflammasomes and fibrosis[J]. Front Immunol, 2021, 12:643149.
doi: 10.3389/fimmu.2021.643149
URL
|
| [16] |
Cui J, Hong PP, Li ZZ, et al. Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet[J]. Int Immunopharmacol, 2023, 120:110353.
doi: 10.1016/j.intimp.2023.110353
URL
|
| [17] |
Liao Y, Tan RZ, Li JC, et al. Isoliquiritigenin attenuates UUO-induced renal inflammation and fibrosis by inhibiting mincle/syk/NF-kappa B signaling pathway[J]. Drug Des Devel Ther, 2020, 14:1455-1468.
doi: 10.2147/DDDT.S243420
URL
|
| [18] |
He Y, Deng B, Liu SL, et al. Myeloid Piezo1 deletion protects renal fibrosis by restraining macrophage infiltration and activation[J]. Hypertension, 2022, 79(5):918-931.
doi: 10.1161/HYPERTENSIONAHA.121.18750
URL
|
| [19] |
Di XP, Li Y, Wei JW, et al. Targeting fibrosis: from molecular mechanisms to advanced therapies[J]. Adv Sci, 2025, 12(3):2410416.
doi: 10.1002/advs.v12.3
URL
|
| [20] |
Li L, Fu HY, Liu YH. The fibrogenic niche in kidney fibrosis: components and mechanisms[J]. Nat Rev Nephrol, 2022, 18(9):545-557.
doi: 10.1038/s41581-022-00590-z
pmid: 35788561
|
| [21] |
Toda N, Mukoyama M, Yanagita M, et al. CTGF in kidney fibrosis and glomerulonephritis[J]. Inflamm Regen, 2018, 38:14.
doi: 10.1186/s41232-018-0070-0
pmid: 30123390
|
| [22] |
Zhao X, Kwan JYY, Yip K, et al. Targeting metabolic dysregulation for fibrosis therapy[J]. Nat Rev Drug Discov, 2020, 19(1):57-75.
doi: 10.1038/s41573-019-0040-5
pmid: 31548636
|
| [23] |
El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field[J]. J Am Soc Nephrol, 2024, 35(1):103-116.
doi: 10.1681/ASN.0000000000000242
URL
|
| [24] |
Dhakal AK, Shrestha D, Preston R, et al. Acute post-streptococcal glomerulonephritis in children-treatment standard[J]. Nephrol Dial Transplant, 2025, 40(10):1843-1853.
doi: 10.1093/ndt/gfaf130
URL
|
| [25] |
Yashima A, Mizuno M, Yuzawa Y, et al. Mesangial proliferative glomerulonephritis in murine malaria parasite, Plasmodium chabaudi AS, infected NC mice[J]. Clin Exp Nephrol, 2017, 21(4):589-596.
doi: 10.1007/s10157-016-1339-8
URL
|
| [26] |
Qi X, Pu YN, Chen FY, et al. Schistosome egg antigen stimulates the secretion of miR-33-carrying extracellular vesicles from macrophages to promote hepatic stellate cell activation and liver fibrosis in schistosomiasis[J]. PLoS Negl Trop Dis, 2023, 17(5):e0011385.
doi: 10.1371/journal.pntd.0011385
URL
|